287 related articles for article (PubMed ID: 12967139)
1. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
Koletsky AJ; Guerra ML; Kronish L
Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
[TBL] [Abstract][Full Text] [Related]
4. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
[TBL] [Abstract][Full Text] [Related]
6. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W; Ackler J; Tijani L; Leighton J
Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
[TBL] [Abstract][Full Text] [Related]
13. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
[TBL] [Abstract][Full Text] [Related]
14. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
Mayordomo JI; Milla A; Morales S; Yubero A; Lorenzo A; Baena JM; Modolell A; Sanz J; Illarramendi J; Garcia MJ; Machengs I; Burrilo MA; Tres A
Clin Breast Cancer; 2004 Jun; 5(2):131-5. PubMed ID: 15245617
[TBL] [Abstract][Full Text] [Related]
15. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
Abratt RP; Brune D; Dimopoulos MA; Kliment J; Breza J; Selvaggi FP; Beuzeboc P; Demkow T; Oudard S
Ann Oncol; 2004 Nov; 15(11):1613-21. PubMed ID: 15520061
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Chittoor S; Berry W; Loesch D; Logie K; Fleagle J; Mull S; Boehm KA; Zhan F; Asmar L
Clin Genitourin Cancer; 2006 Dec; 5(3):212-8. PubMed ID: 17239275
[TBL] [Abstract][Full Text] [Related]
17. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
Georgoulias V; Androulakis N; Bouros D; Kouroussis C; Chatzakis K; Papadakis M; Apostopoloulou F; Georgopoulou T; Kotsakis T; Souklakos J; Hatzidaki D; Vlachonikolis J; Panagos G
Lung Cancer; 1998 Sep; 21(3):213-20. PubMed ID: 9857999
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
Sewak S; Chachoua A; Hamilton A; Taneja S; Lee J; Utate M; Sorich J; Muggia FM
Anticancer Drugs; 2003 Jan; 14(1):67-72. PubMed ID: 12544260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
